Blood Signature of Pre-Heart Failure: A Microarrays Study by Smih, Fatima et al.
Blood Signature of Pre-Heart Failure: A Microarrays
Study
Fatima Smih
1*, Franck Desmoulin
1, Matthieu Berry
1,2, Annie Turkieh
1, Romain Harmancey
1, Jason
Iacovoni
1, Charlotte Trouillet
1,2, Clement Delmas
1,2, Atul Pathak
1,2, Olivier Lairez
1,2, Franc ¸ois Koukoui
1,
Pierre Massabuau
1,2, Jean Ferrieres
2, Michel Galinier
1,2, Philippe Rouet
1,2
1INSERM/Universite Paul Sabatier UMR 1048, Institut des Maladies Me ´taboliques et Cardiovasculaires (I2MC), Toulouse, France, 2Rangueil Hospital University, Cardiology
Department, Toulouse, France
Abstract
Background: The preclinical stage of systolic heart failure (HF), known as asymptomatic left ventricular dysfunction (ALVD),
is diagnosed only by echocardiography, frequent in the general population and leads to a high risk of developing severe HF.
Large scale screening for ALVD is a difficult task and represents a major unmet clinical challenge that requires the
determination of ALVD biomarkers.
Methodology/Principal Findings: 294 individuals were screened by echocardiography. We identified 9 ALVD cases out of
128 subjects with cardiovascular risk factors. White blood cell gene expression profiling was performed using pangenomic
microarrays. Data were analyzed using principal component analysis (PCA) and Significant Analysis of Microarrays (SAM). To
build an ALVD classifier model, we used the nearest centroid classification method (NCCM) with the ClaNC software
package. Classification performance was determined using the leave-one-out cross-validation method. Blood transcriptome
analysis provided a specific molecular signature for ALVD which defined a model based on 7 genes capable of
discriminating ALVD cases. Analysis of an ALVD patients validation group demonstrated that these genes are accurate
diagnostic predictors for ALVD with 87% accuracy and 100% precision. Furthermore, Receiver Operating Characteristic
curves of expression levels confirmed that 6 out of 7 genes discriminate for left ventricular dysfunction classification.
Conclusions/Significance: These targets could serve to enhance the ability to efficiently detect ALVD by general care
practitioners to facilitate preemptive initiation of medical treatment preventing the development of HF.
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Introduction
The risk for developing heart failure (HF) in Western countries
is estimated to be 33%, with a 8 year post-diagnosis mortality rate
of 75% [1] and the annual cost of treatment in the US was
estimated at $37.2 billion in 2009 [1]. Epidemiologic studies have
demonstrated that cardiovascular risk factors such as hypertension,
diabetes and obesity are precursors of HF [1]. These factors
induce modification of the myocardium structure and lead to
functional alterations of the heart [2] including a reduction in the
left ventricular ejection fraction (LVEF). Identification of patients
at the ‘‘pre-heart failure’’ stage can prevent the development of HF
through the initiation of adapted medical and non-medical
strategies. This silent preclinical state (pre-heart failure) is referred
as asymptomatic left ventricular dysfunction (ALVD) and can only
be diagnosed by transthoracic echocardiography. ALVD, com-
mon in the general population, leads to a high risk of developing
overt HF. Indeed, compared to individuals with normal LVEF,
ALVD subjects have a 12-fold increase in the annual rate of
hospitalization for first-event HF [3] and a 4-fold increase in the
risk of death over a 6-year period [2]. Effective large-scale
screening for ALVD, at present a difficult task representing a
major unmet clinical challenge, requires a determination of ALVD
biomarkers.
Despite the fact that screening for ALVD has been advocated
for over a decade [3,4], there are no ALVD biomarkers. Indeed,
ALVD diagnosis requires a sophisticated echocardiographic
analysis, which is both time-consuming and costly, and is not
applicable to the large population of individuals at risk. The lack of
biomarker(s) is of importance because ALVD is highly prevalent
due to the general increase in cardiovascular risk factors [5].
ALVD has become established as a predictive early indicator of
severe HF [6]. Follow-up studies have shown that ALVD subjects
display an average annual chronic heart failure rate of 4.9 to 20%,
with a mortality rate of 5.1 to 10.5% [7,8]. Such observations were
recently confirmed in a 5-year survival rate analysis that showed a
death rate of 31% for subjects suffering from ALVD and of 47%
for patients with systolic HF [9]. Finally, the SOLVD study
demonstrated that the treatment of ALVD results in a significantly
delayed occurrence of HF [10]. Therefore, it is of clinical
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before they develop overt HF.
The objective of the present study was to evaluate the impact of
ALVD on the human transcriptome and to identify a specific
molecular signature based on differential gene expression. Ideally,
the molecular signature should be independent of cardiovascular
risk factors (such as hypertension, diabetes, obesity, dyslipide-
mia…) and should be useful to sort ALVD individuals among
subjects with cardiovascular risk factors. Moreover, the transcrip-
tome analysis allowed us to perform a global analysis without prior
knowledge or hypothesis of the gene whose expression could be
affected by the disease.
We analyzed white blood cell transcriptomes since gene
expression patterns in peripheral blood has been validated in
humans [11] as a basis for the detection and diagnosis of diseases
such as chronic [12,13] and acute heart failure [14]. Indeed, the
blood is a dynamic and interactive tissue that communicates with all
cells of the body and can therefore display perturbations indicative
of disease. Previous work have shown that blood cells share 84% of
their transcriptome with the heart [15] and that some gene
regulations in blood are similar to other organs such as the heart
[13,14]. Thus, peripheral blood is likely to become a useful resource
in the diagnosis of systemic diseases, selection of treatment methods
and disease outcome prediction [15]. In this work we show that
white blood cells retain information of ALVD and provide a set of
genes that could be used to pre-screen patients for ALVD before
time-consuming echocardiographic confirmation of the disease.
Results
Patient Inclusions
Allthe 294 subjects underwent transthoracic echocardiography for
left ventricular ejection fraction (LVEF) assessment (Fig. 1). Healthy
volunteers (HI) without cardiovascular risk or echocardiographic
abnormalitieswere recruited from the generalpopulation. Individuals
with cardiovascular risk factors and normal left ventricular ejection
fraction (RF) and individuals with cardiovascular risk factors and
asymptomatic abnormal left ventricular ejection fraction (ALVD)
were from the atherosclerosis prevention center. Patients with stable
systolic chronic heart failure (CHF) were recruited from the
cardiology department at Rangueil Hospital, Toulouse. We used a
threshold value of LVEF,45% to sort individuals into 4 groups: HI,
RF with LVEF$45%, ALVD, and CHF with LVEF,45%. We
identified 9 ALVD cases out of the 128 subjects tested with
cardiovascular risk factors. The set of cardiovascular risk factors used
to match the study groups were determined based on the
characteristics of the ALVD subjects (n=9): mean age 58 years
old, 78% male, 44% hypertensive, 33% diabetes, 44% obesity, 56%
dyslipidemia and 22% heredity. We defined two comparative groups:
1- (RF) individuals with cardiovascular risk factors and normal left
ventricular ejection fraction (62,LVEF,81%); 2- (ALVD) individ-
uals with cardiovascular risk factors and systolic ALVD
(32,LVEF#44%). Two additional groups were used as controls:
3- (HI, negative control) Healthy volunteers without cardiovascular
risk or echocardiographic abnormalities and 4- (CHF, positive
control) patients with chronic stable systolic heart failure
(18,LVEF,44%). Moreover, all individuals were extensively
phenotyped to check for clinical and biochemical parameters.
Medications and biochemical data were not significantly different
between comparative groups (RF and ALVD) (Table 1).
BNP Measurements
Healthy individuals had plasma BNP levels within the range
1169 pg/ml. Plasma BNP levels were not statistically different
between ALVD (27623 pg/ml) and RF (15610 pg/ml) patients,
but were significantly increased in CHF (1646151 pg/ml)
(Table 1).
ALVD predictive model based on white blood cell
transcriptome
We used the RNG-MRC 25k human pangenomic glass
microarrays from the National Genopole Network to analyze
blood gene expression of 25,341 genes. An unsupervised PCA
analysis of the expression data was able to cluster patients into
their respective groups: HI, RF, ALVD and CHF (Fig. 2) and
revealed that blood gene expression profiles provide a molecular
signature characteristic of ALVD. In order to build an ALVD
predictive model, we used the nearest centroid classification
method (NCCM) from the ClaNC software package [16]. NCCM
provided a set of genes whose expression profile led to a 100%
successful classification of ALVD patients out of the 4 groups of
individuals. We further tested the strength of our model of gene
expression-based group prediction by leave-one-out cross-valida-
tion method [17]. The classifier model accuracy and precision
computed from the confusion matrix (Table 2) were 83% and
78%, respectively. The Fisher’s exact test P-value (n=18,
P=0.015) pointed out the robustness of the model.
Additional ALVD patient group validation
In addition to our original patient cohort, we obtained blood
samples from 8 additional ALVD and 8 RF individuals not
matched for cardiovascular risk factors. These additional subjects
fulfilled the ALVD parameter definition as they were in NYHA I
class with an EF,45%, lacked HF symptoms, had low plasma
BNP levels (25611 pg/ml) which was not significantly different
from the initial ALVD group (P=0.87) (Table 3). White blood
cell gene expression analysis further validated using the ClaNC
ALVD predictive model which gives 75% of true positive rate and
100% of true negative rate. Thus, the accuracy and precision of
the prediction were 87% and 100%, respectively (Fisher’s exact
test P-value=0.007; n=16).
Discriminant genes
ClaNC defined a set of discriminant genes for the ALVD group
including ALK, SLC43A2, NGFB, FBXW7, TMEM79, UBN1
and FECH (Table 4). SAM software analysis revealed that these
genes were significantly differentially expressed between RF and
ALVD with a false discovery rate ranging between 1.4 and 3.2
which is below 5%, a value generally used in transcriptome studies
and is indicative of good reliability of the differential expression of
these genes. Moreover, differential expression of these 7 genes in
white blood cells from RF and ALVD groups was confirmed by
realtime qPCR (Figure S1). Using human heart samples (right
appendage) from patients undergoing coronary by-pass during
heart surgery, we observed a similar regulation (induction or
repression) that was statistically significant for 3 genes (UBN1,
NGF, FECH) when comparing gene expression levels in the no
HF vs the CHF group. ALK expression displayed a tendency to be
increased in heart from heart failure patients but the difference
was not statistically significant (p=0.15) (Figure S2).
Moreover, Ingenuity’s Pathway Analysis revealed that three
genes encoded membrane proteins: the kinase ALK, TMEM79
and SLC43A2. FECH is a mitochondrial protein and FBXW7
encodes a cytoplasmic component of E3 ubiquitin protein ligase,
which regulates the proteolytic machinery. UBN1 is a transcrip-
tion factor involved in the formation of senescence-associated
heterochromatin foci. NGFB (Nerve Growth Factor Beta) is a
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20414Figure 1. Flow chart of recruitment protocol involving 294 subjects and overall study design. Healthy volunteers (HI) were recruited from
the general population, individuals with cardiovascular risk factors (RF) were from the atherosclerosis prevention center and patients with chronic
heart failure (CHF) were recruited from the cardiology department at Rangueil Hospital, Toulouse. All subjects underwent transthoracic
echocardiography for left ventricular ejection fraction (LVEF) assessment. We used a threshold value of LVEF,45% to sort individuals into 4 groups: HI
(light blue), RF with LVEF$45% (dark blue), ALVD (red), and CHF (orange) with LVEF,45%. We identified 9 ALVD cases out of the 128 subjects tested
with cardiovascular risk factors. We used the set of cardiovascular risk factors (age, gender, arterial hypertension, diabetes, obesity, dyslipidemia and
heredity) based on the characteristics of the ALVD subjects to match the study groups (n=9). White blood cell gene expression profiling was
performed using pangenomic microarrays for all 4 groups. Data were statically analyzed using unsupervised primary component analysis (PCA) and
by Significance Analysis of Microarrays (SAM software) which defined the false discovery rate. Then to build an ALVD classifier model, we used the
nearest centroid classification method (NCCM) with the ClaNC software package. Classification performance was determined using the leave-one-out
cross-validation method. Expression levels of 7 genes capable of discriminating ALVD were compared between the 4 groups and each gene’s
capability to discriminate patients with LVEF,45% was evaluated using Receiver Operating Characteristic (ROC) analysis.
doi:10.1371/journal.pone.0020414.g001
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involved in the development, maintenance of function and
regeneration of nerve cells in the heart [18].
We next looked for the pertinence of each of these genes with
respect to ALVD subject classification. Box-and-whisker plots,
which depict variations in gene expression levels, showed that
expression of NGFB, TMEM79 and FBXW7 was significantly
down-regulated in ALVD group (Fig. 3Aa, b, c), whereas FECH,
ALK, UBN1 and SLC43A2 expression were significantly
increased in ALVD cases (Fig. 3Ad, e, f, g).
A series of ROC curves were created for each of the proposed
discriminant genes as related to the incidence of left ventricular
dysfunction (LVEF,45%) (Fig. 3B). Six genes out of seven
(NGFB, TMEM79, FECH, FBXW7, ALK, UBN1) statistically
differed from the null hypothesis (p,0.005 or p,0.0001, Table 5)
and provided a good discrimination (no overlap in the two
distributions). The area under the curve (AUC), ranged from 0.78
to 0.92 for predicting left ventricular dysfunction. Only the
SLC43A2 gene harbored a weak AUC (0.59) and was a poor
predictor (p=0.35; Table 5).
Discussion
Epidemiological echocardiographic studies, have revealed that
ALVD has a prevalence of 0.9 to 12.9%, depending on the
definition of the threshold value for LVEF (,30% up to ,54%)
and the population studied [2,19,20,21,22]. We used a threshold
value of LVEF,45% to screen for truly asymptomatic subjects in
a population possessing cardiovascular risk factors and found an
ALVD prevalence of 7% (9 ALVD out of 128 subjects tested with
cardiovascular risk factors), in line with values reported in previous
works (6.7%) [2].
Table 1. Cardiovascular risk factors, clinical and biochemical parameters of study groups.
Groups HI RF ALVD CHF
Age (years) 55 (72-45) 55 (69-38) 58 (84-31) 55 (83-23)
M a l e % 7 87 87 86 7
Hypertensive % 0 44 44 44
Diabetes % 0 33 33 33
Obesity % 0 44 44 56
Dyslipidemia % 0 56 56 44
Heredity % 0 33 22 11
BMI 24632 8 632 9 643 0 65
Systolic blood pressure (mm Hg) 128616 138612 123617 124619
Diastolic blood pressure (mm Hg) 81698 0 614 75612 7669
Heart rate 64 (45-86) 64 (57-72) 70 (54-87) 78 (60-102)
Medications
Statines % 0 22 55 44
b Blockers % 0 11 44 78
=
ARBs or ACEIs % 0 48 55 88
=
Labs (means ± s.d.)
BNP (pg/ml) 11691 5 610 27623 1646151
$
Na+ (mM) 140611 4 0 611 3 9 621 3 8 64
creatinine (mM) 80668 3 699 6 623 126673
Hb (g/dl) 14.761.1 14.361.1 14.161.8 13.461.8
Leukocytes (cells/ml) 573561225 615961433 676561533 857162734
Lymphocytes (cells/ml) 18656412 19886428 19186499 18986677
Neutrophils (cells/ml) 34986898 363061073 410761153 604962619
Echocardiography
LVEF % 73 (65-81) 71 (62-81)* 39 (32-44) 33 (18-44)
LVEDD (mm) 48 (53-44) 49 (53-42)* 61 (66-48) 61 (64-56)
Shortening fraction % 39 (44-30) 37 (45-28)* 23 (27-18) 20 (35-8)
Proportion of individuals with the indicated risk factor for each of the 4 groups of the study are indicated as percentages or averaged value:- HI, Healthy volunteers
without cardiovascular risk or echocardiographic abnormalities; RF, individuals with cardiovascular risk factors and normal left ventricular ejection fraction (LVEF); ALVD,
asymptomatic left ventricular dysfunction individuals with cardiovascular risk factors and abnormal left ventricular ejection fraction; CHF, Patients with chronic stable
systolic heart failure. All individuals were extensively phenotyped to check for clinical and biochemical parameters. Family history of coronary artery disease is defined as
a family history of coronary event before 55 years in men and/or 65 years in women occurring in first degree relatives.
*indicates P,0.05 for statistical comparison between RF and ALVD groups.
$indicates P,0.05 for statistical comparison between ALVD and CHF groups. BNP, B-type natriuretic peptide. ARBs: angiotensin receptor blockers. ACEIs : angiotensin
converting enzyme inhibitors.
=indicates P,0.05 for statistical comparison between groups. LVEDD : left ventricular end-diastolic diameter. LVESD : left ventricular end-systolic diameter. Shortening
fraction %=(LVEDD2LVESD)/LVEDD6100.
doi:10.1371/journal.pone.0020414.t001
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proBNP (NT-ProBNP), released from the heart in response to
pressure and volume overload, have become the main biomarkers for
assessing HF (reviewed in [23]). BNP was shown to be of limited use
in the detection of ALVD in diabetic patients[24]. While the negative
predictive value of NT-ProBNP was 96 to 100% [25,26], its positive
predictive value ranged from 6 to 33%, which limited its use in
ALVD detection [25,26]. In our study, ALVD individuals (test and
validation groups together) had plasma BNP levels within the
physiological range [23] : (26618 pg/ml; n=17). As generally
observed in CHF patients, the symptomatic and positive controls of
this study, BNP levels were significantly increased (1646151 pg/ml).
These values, in accordance with Daniels and Maisel [23], confirm
that the ALVD subjects selected in this study are truly asymptomatic
individuals. Since BNP levels could not be used satisfactorily for
ALVD detection within our subjects, we attempted to find new
biomarkers using holistic approaches. Considering DNA microarrays
are powerful tools allowing for large scale screenings, we used the
RNG-MRC 25k human pangenomic glass microarrays from the
National Genopole Network to analyze blood gene expression of
25,341 genes. An unsupervised Principal Component Analysis (PCA)
of the global gene expression data clustered individuals into their
respective groups (HI, RF, ALVD and CHF) and revealed a
molecular signature characteristic of ALVD. Since it is difficult to
define gene sets belonging to each clusters in most implementation of
PCA [27] and in order to build an ALVD classifier model, we used
the nearest centroid classification method (NCCM) which provides
Figure 2. Unsupervised primary component statistical analysis (PCA) of blood transcriptome data reveals a molecular signature for
ALVD. Three dimensional plot of the three first components(PC1, PC2, PC3) of the blood gene expression data from healthy subjects (HI, light blue),
cardiovascular risk factor individuals (RF, dark blue), individuals with asymptomatic left ventricular dysfunction groups (ALVD, red) and chronic heart
failure patients (CHF, orange). These three components can classify subjects according to their group and distribute the subjects in grouped locations
in the defined space. Numbers in colors indicate subjects’ identities. The relative expression level used is defined by the ratio obtained with the tested
sample to the signal obtained using the common reference, an equimolar mix of all the RNA used to generate a reference signal.
doi:10.1371/journal.pone.0020414.g002
Table 2. Leave-one-out’s confusion matrix.
ALVD Individuals RF Individuals
Classified as LVEF,45 (true positive)
78%
(false positive)
11%
Classified as LVEF$45% (false negative)
22%
(true negative)
89%
Classification performance of the nearest centroid classifier was determined
using leave-one-out cross-validation method. Calculation of the classifier model
accuracy and precision by standard formulae provided 83% and 78%,
respectively. Fisher’s exact test P-value (n=18) P=0.015.
doi:10.1371/journal.pone.0020414.t002
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expression profile led to the classification of ALVD subjects out of the
four groups of individuals. We further tested the strength of our
model of gene expression-based group prediction by leave-one-out
cross validation, a technique recognized for its small bias [17], which
utilizes a single observation from the original sample as the validation
data and the remaining observations as the training data. The
confusion matrix from the leave one-out cross-validation results, led
us to conclude that the defined pool of genes efficiently classifies
ALVD subjects. Moreover, the test of additional patients included in
an ALVD patient validation group showed that the accuracy (87%)
and the precision (100%) of the gene expression based predictive
model were close to the ones determined by leave-one-out cross-
validation (88 and 78% for accuracy and precision, respectively).
Interestingly, the decrease in NGFB gene expression that we
observed in white blood cells was previously reported in both
human and experimental heart failure [28]. Our data suggest that
NGFB down-regulation could occur earlier in blood, in pre-heart
failure state. Moreover, SAM analysis revealed significant
overexpression EGR1 and CCR2 genes in CHF group (data not
shown) in agreement with previous report [13].
UBN1, NGF and FECH genes displayed similar statistically
significant regulation (up or down regulated) in hearts samples
from heart failure patients (Figure S2) but expression of the three
remaining genes (TMEM79, FBXW7 and SLC43A2) could not be
quantified, probably because of their low expression in heart. This
is in accordance with other studies showing that white blood cells
express a large number of heart genes but not all [15] and that
some genes expressions regulations in heart are also observed in
white blood cells which might serve as surrogate markers for heart
failure [14].
The data presented in this paper has the potential to provide
tools for ALVD screening. We have chosen to match cardiovas-
cular risk factors within comparative groups (RF and ALVD),
which limited the number of blood samples used in the analysis,
but also resulted in the determination of an ALVD blood
transcriptome signature as well as the elucidation of putative
marker genes. One advantage of this prospective monocenter
study is that the microarrays and clinical data quality were
homogeneous. Gene expression analysis has recently undergone a
tremendous evolution and could before long be carried out in a
routine clinical setting (outpatient department, general practice)
which would represent a cost effective method to identify ALVD
subjects and prevent HF development. We anticipate that large
screen of population at risk for ALVD examinated by primary-
care physician could be screened at low cost by blood microfluidic
qPCR and if positive for ALVD would be addressed to
echocardiography for ALVD confirmation. This strategy would
identify subject in the early phase of this silent disease and prevent
them from being symptomatic by early medication and appropri-
ate lifestyle-related advices.
Materials and Methods
Study design and population
The present study was conducted with 294 individuals (Healthy
volunteers (HI, n=22), arteriosclerosis prevention (individuals
with cardiovascular risk factors, n=128) and cardiology depart-
ments (patients with chronic stable heart failure (CHF, n=144) at
the French Medical University Hospital of Toulouse (Fig. 1 and
Table 1). All patients underwent echocardiography and left
ventricular ejection fractions (LVEF) were determined by contour
Table 3. Cardiovascular risk factors, clinical and biochemical
parameters of the ALVD validation group (n=8) and RF
individuals (n=8).
Groups ALVD Individuals RF
LVEF % 39 (20-45) 74 (65-81)*
Age (years) 63 (75-40) 67 (83-55)
Male % 87 100
Hypertensive % 62 37
Diabetes % 12 25
Obesity % 01 2
Dyslipidemia % 50 37
Heredity % -0
BMI 25632 8 65
Systolic blood pressure (mm Hg) 144619 145612
Diastolic blood pressure (mm Hg) 82610 8668
Labs (mean ± s.d.)
BNP (pg/ml) 25611 1469
Na+ (mM) 14062 14061
creatinine (mM) 110638 92612
Hb (g/dl) 14.060.9 14.460.4
Leukocytes (cells/ml) 604361041 668261360
Lymphocytes (cells/ml) 14336332 19596700
Neutrophils (cells/ml) 39756744 30496668
*indicates P,0.05 for statistical comparison between RF and ALVD validation
groups.
doi:10.1371/journal.pone.0020414.t003
Table 4. ClaNC defined set of 7 discriminant genes for ALVD.
Gene symbol Ensembl accession number Full gene name Protein location
ALK ENSG00000171094 Anaplastic lymphoma receptor tyrosine kinase plasma membrane
SLC43A2 ENSG00000167703 Solute carrier family 43, member 2 plasma membrane
NGFB ENSG00000134259 Nerve growth factor (beta polypeptide) Extracellular space
FBXW7 ENSG00000109670 F-box and WD repeat domain containing 7 Nucleus; cytoplasm
TMEM79 ENSG00000163472 Transmembrane protein 79 plasma membrane
UBN1 ENSG00000118900 Ubinuclein 1 Nucleus
FECH ENSG00000066926 Ferrochelatase Mitochondrion
Gene symbol, Ensembl accession number, full gene name and protein location, as provided by Ingenuity’s Pathway Assist software, are indicated.
doi:10.1371/journal.pone.0020414.t004
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According to the European guidelines [30], left ventricular systolic
dysfunction was defined by a LVEF,45%. We defined two
comparative groups: 1- (RF) individuals with cardiovascular risk
factors and normal left ventricular ejection fraction; 2- (ALVD,
n=9) individuals with cardiovascular risk factors and systolic
ALVD.
Right ventricular function was evaluated during the echocar-
diography examination with the tricuspid annular plane systolic
excursion (TAPSE) index and/or the S-wave velocity, patients
presenting a TAPSE index ,16 mm and/or a S-wave ,10 cm/s
were excluded from the study. Two additional groups were used as
controls: 3- (HI, n=22) Healthy volunteers without cardiovascular
risk or echocardiographic abnormalities and 4- (CHF, n=144)
Patients with chronic stable systolic heart failure. CHF etiology
was 33% ischemia, 11% arterial hypertension, 11% valvular
disease, 44% dilated idiopatic cardiomyopathy. Atrial fibrillation
was found in 33% of CHF patients. Exclusion critera were
presence of infarct or recent angor (,6 months), infiltrative
cardiomyopathy, cerebral vascular event, kidney failure, liver
failure, blood disease, ongoing cancer or cured since 5 years or
less, toxicomania and alcohol abuse, psychiatric disorders and
participation to a clinical trial within the last 30 days. Using SAS
software, we defined groups of 9 subjects perfectly matched to the
ALVD group for HF risk factors such as age, gender, arterial
hypertension, diabetes, obesity, dyslipidemia and heredity. BNP
was assessed using the Centaur Bayer kit (Bayer HealthCare,
France) and a Centaur (Siemens, France) hospital automat as
recommended by the manufacturers. This research protocol was
approved by the institutional review boards and ethics committee.
All participants gave written informed consent (ClinicalTrials.gov
number: NCT01024049).
Figure 3. Expression levels for 7 genes discriminate the ALVD
group. A. a–g Relative expression levels of the 7 genes, sorted by the
nearest centroid classifier, are assessed for HI (light blue), RF (dark blue),
ALVD (red) and CHF (orange) groups. The relative expression level used
is defined by the ratio obtained with the tested sample to the signal
obtained using the common reference, an equimolar mix of all the RNA
Table 5. ROC curve statistical data.
Gene AUC 95% CI P value
NGFB 0.91 0.82–1.00 ,0.0001
TMEM79 0.88 0.76–1.00 ,0.0001
FBXW7 0.91 0.81–1.01 ,0.0001
FECH 0.92 0.82–1.02 ,0.0001
ALK 0.88 0.76–1.00 ,0.0001
UBN1 0.78 0.62–0.94 =0.0036
SLC43A2 0.59 0.38–0.80 =0.3589
Area under curve (AUC), 95% confidence interval (CI) and P values are indicated.
doi:10.1371/journal.pone.0020414.t005
used to generate a reference signal. The box plot presents the median,
lower and upper quantiles (25
th,7 5
th percentiles) lower and upper
whiskers represent the 10th and 90th percentiles. * P,0.05 where
indicated, estimated by one-way ANNOVA. B. Receiver-operating
characteristic (ROC) analysis of ALVD discriminant genes using HI with
RF (LVEF$45% as disease free) and ALVD with CHF (LVEF,45% as left
ventricular dysfunction) groups. Area under curve (AUC), confidence
interval and P values to find an AUC value of 0.5 (null hypothesis) for
each gene are depicted in Table 5. ROC curves for each of the 7 genes
are displayed on a single figure. With the exception of SLC43A2, ALVD
discriminant genes are also CHF biomarkers i.e. left ventricular
dysfunction biomarkers.
doi:10.1371/journal.pone.0020414.g003
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After ethical committee approval, all patients included in the
sub-study gave their informed consent for sample collection and
molecular analysis prior to their inclusion. Patients were carefully
selected by the physicians from Department of Cardiology,
Toulouse University hospital prior to cardiac surgery for coronary
by-pass due to coronary disease. Samples from right auricle
appendages were collected from the department of cardiovascular
surgery of Toulouse University Hospital at the beginning of
cardiac surgery and were of extra corporeal circulation. Samples
were immediately washed in cold buffer, snap frozen in liquid
nitrogen and maintained at 280uC until analysis. Total RNA was
isolated from the myocardium by using TRIzol reagent (Invitro-
gen, France) as described by the manufacturer. RNA integrity was
checked by capillary electrophoresis using an Experion (Biorad)
apparatus.
Microarrays Analysis
We collected blood samples in 8 ml BD CPT vacutainer tubes
that were processed immediately after collection according to the
manufacturer’s protocol. Total RNA was purified from collected
white blood cells using the RNeasy kit (Qiagen) in a Qiacube
(Qiagen) automated protocol. Total RNA integrity was checked by
capillary electrophoresis (Experion, Bio-Rad). Samples with RNA
Quality Indicator $8.5/10 were selected for analysis. Total RNAs
werepreciselyquantifiedusingRiboGreenandaVictor
TMX52030
multilabel reader (Perkin Elmer). Total RNA (300 ng) were used for
fluorescent labeling (QuickAmp Labeling, Agilent). Fluorescent
RNAs were further purified on RNeasy columns. We used a pooled
reference sample as a common reference for all hybridizations [31].
Labeled RNA were hybridized to human pangenomic glass
microarrays from the consortium Reseau National des Ge ´nopole
France and Medical Research Council, England; consisting of
,25,000 51-mer oligonucleotide probes. After standard hybridiza-
tion, glass arrays were washed on a Ventana robotized apparatus
and scanned using a GenePix 4000 scanner (Axon).Scanned images
were processed by X-dot reader software with operator validation.
Microarray data were deposited in the GEO database
(#GSE21125) and followed MIAME requirements.
Real time quantitative PCR analysis
Genomic DNA was removed from RNA samples by DNAfree
kit according to the manufacturer protocol (Ambion). Reverse
transcription was carried-out using 150 ng total RNA and
Superscript III according to the manufacturer protocol (Invitro-
gen). Realtime quantitative PCR was performed in a MyiQ real
time PCR detection system using Sybergreen and as previously
described [32]. Oligos were synthetised by Eurogentec company
and designed with PerlPrimer [33] and were as follow: hNGF
forward, 59-GAGGTGCATAGCGTAATGTC-39 and reverse 59-
TGCTGAAGTTTAGTCCAGTG-39; hTMEM79 forward, 59-
CATCAAATGGGACTGTGGTG-39 and reverse 59-TTAA-
AGGTGGGAAGTTACAGG-39; hALK forward, 59-AAGCTG-
TACTGTCCCACCTAAC-39 and reverse 59-CATATTGGCA-
GTCAGCGAAGAG-39; hFECH forward, 59-AGTAGACTTT-
GAGTGACCGTCC-39 and reverse 59-AAAGAATTGAAGCA-
GGCCCTTG-39; hUBN1 forward, 59-AAATCAAGGTGAAG-
GAATCGTC-39 and reverse 59-TCCTGTTTGGTGATCT-
GAG-39; hFBXW7 forward, 59-GGATTGATGAACCATTG-
CAC-39 and reverse 59-ATGTTCTCAGACATTTGCCT-39;
hSLC43A2 forward, 59-TTTGGTGGGATGTGTATGAC-39
and reverse 59-CATAGAAGAGCTTGATTCCTG-39; hGUS
forward, 59-CTCATTTGGAATTTTGCCGAT-39 and reverse
59-CCGAGTGAAGATCCCCTTTTT-39. hGUS was used as a
normalization gene since its expression did not significantly
fluctuate between groups in this study.
Statistical Analysis
Data normalization was performed in ÆÆRææ (http://www.r
-project.org/index.html) and the bioconductor package limma.
Two-color GenePix files were normalized within arrays using
the ‘‘loess’’ method and between arrays with ‘‘Rquantile’’
normalization. Five groups of 9 samples were established and
used to calculate p-values with respect to the analysis of variance
(aov) within each group. Log-ratios were extracted for probes in
which the aov p-value was less than or equal to 0.001, resulting
in 1055 probes before unsupervised statistical analysis by
principal component analysis (PCA) with SIMCA P
+ software
(Umetrics). Class prediction was done with the nearest centroid
method using ClaNC software, which is known to make the
classifier more accurate by reducing the effect of noisy genes
[16]. Significance Analysis of Microarrays (SAM) computed by
SAM 3.0 software which can compute the false discovery rate
(FDR) for the differentially expressed genes was used as ‘‘power
analysis’’ [34]. ROC curve analysis was performed using
MedCalc software (www.medcalc.be). Continuous variables
are presented as mean 6 SD and categorical as numbers and
percentages. Continuous variables were compared with the use
of Student’s t-test or Mann-Whitney rank sum test when
normality or equal variance test failed. Categorical variables
were compared with the use of the Pearson chi-square (sigma
stat) otherwise specified in the text.
Supporting Information
Figure S1 Realtime qPCR analysis of white blood cell
genes expression. RF: cardiovascular risk factors patients;
ALVD: asymptomatic left ventricular dysfunction individuals.
Arbitrary units are indicated (A.U.) after normalisation to the
reference gene. * p,0.05; **p,0.01; *** p,0.001 in Student’s
t test.
(TIF)
Figure S2 Realtime qPCR analysis of genes expression
in humant heart. Cont: Control patients without heart failure;
CHF: Chronic heart failure patients. Arbitrary units are indicated
(A.U.) after normalisation to the reference gene. * p,0.05;
**p,0.01; *** p,0.001 in Student’s t test.
(TIF)
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